Rational Design of a New Generation of Therapeutic Oligonucleotide Tools
Rational Design of a New Generation of Therapeutic Oligonucleotide Tools
Webinar

Rational Design of a New Generation of Therapeutic Oligonucleotide Tools

Webinar Overview

This webinar will present new chemically modified oligonucleotide tools with the potential to tackle multifactorial disorders (among them, cancer and related drug resistance issues), while overcoming the limitations of oligonucleotide therapeutics.

Among the different oligonucleotide tools that will be presented, special emphasis will be placed on novel multi-target nanostructures specifically designed to administer several oligonucleotide drugs in a single dose, each of them active against a different therapeutic target. In addition, their functionalization with accessory molecules, such as fluorophores and targeting peptides for monitoring their specific delivery to tumours, will also be discussed.

Tuesday, 5 December 2023, 17:00 CET

Key Learning Topics

  • New chemical modification approaches to increase the biostability of oligonucleotides.
  • Functionalization of therapeutic oligonucleotides with accessory molecules, such as targeting peptides, for their selective delivery to the tumour.
  • Multi-target approaches to deliver multiple oligonucleotide drugs in a single dose.

What to Expect

Presentation of new chemical modification approaches to: i) increase the resistance of oligonucleotide drugs to 3’-exonuclease degradation, ii) create novel robust siRNA prodrugs that can act as substrates for Dicer, and iii) combine multiple oligonucleotide drugs into one single structure that can be selectively cleaved by specific intracellular stimuli, such as endogenous enzymes.

Speakers

Dr. Montserrat Terrazas

Associate Professor - Department of Inorganic and Organic Chemistry (Organic Chemistry Section), Faculty of Chemistry, University of Barcelona, Barcelona, Spain

Montserrat Terrazas received her PhD degree from the University of Barcelona (UB) in 2006. She carried out postdoctoral stays at KU Leuven, Stanford University, and IQAC-CSIC. From 2014 to 2020, she stayed at IRB-Barcelona as a Miguel Servet Fellow. In 2021, she was appointed as an Associate Professor at UB.

https://webgrec.ub.edu/webpages/000007/cat/montserrat.terrazas.ub.edu.html#

Dr. Martial Piotto

Pharma product manager of Biologics solutions

Martial Piotto obtained his Ph.D. in NMR spectroscopy at the University of Purdue, USA (Pr. D. Gorenstein). He then joined Bruker France as head of NMR application where he worked on various aspects of NMR spectroscopy, notably the development of new pulse sequences and HRMAS technology. Over the years, he grew an interest in applications of NMR in the pharmaceutical and medical fields. His work currently focusses on the characterization of Biologics (mAb, vaccines and therapeutic oligonucleotides) by combining NMR and multivariate statistical tools.

Registration

Input value is invalid.

Are you already in contact with your Bruker representative regarding any product inquiries?

We constantly want to improve our service for our customers. In answering the following question you help us to serve your needs even better in the future: What best describes your situation?

By ticking this box, I agree to receive, from time to time, emails from Bruker and its affiliates within the Bruker Group on upcoming events, webinars, our products and services, surveys and Bruker's corporate news.
I can unsubscribe at any time, by contacting Bruker or clicking on the opt-out link in the email if available. For more information on the processing of your personal data, please check Bruker’s Privacy Policy. 

By submitting this form I agree my personal data will be used to process my registration to the webinar. I have read and accepted the Bruker Website Privacy Notice (https://www.bruker.com/privacy-policy.html) and I agree to the Terms of Use (https://www.bruker.com/terms-of-use.html) of the Bruker website.

Already registered and lost your invitation link?

Thank you. The invitation link has been resent.